NCT04094012View on ClinicalTrials.gov

Risk of SDRs Under 3HP and 1HP Regimen for LTBI

PHASE3CompletedINTERVENTIONAL

Enrollment

490

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

October 8, 2023

Study Completion Date

December 15, 2023

Conditions

Latent Tuberculosis Infection

Interventions

DRUG

isoniazid and rifapentine

This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER

NCT04094012 - Risk of SDRs Under 3HP and 1HP Regimen for LTBI | Biotech Hunter | Biotech Hunter